




Instance: composition-en-8a64404ab8208188b8002b2af6aa836e
InstanceOf: CompositionUvEpi
Title: "Composition for enyglid Package Leaflet"
Description:  "Composition for enyglid Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp53be401b554c8b8758dbe7f849ef490a)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - enyglid"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Enyglid is and what it is used for</li>
<li>What you need to know before you take Enyglid</li>
<li>How to take Enyglid</li>
<li>Possible side effects</li>
<li>How to store Enyglid</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What enyglid is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What enyglid is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Enyglid is an oral antidiabetic medicine containing repaglinide which helps your pancreas produce 
more insulin and thereby lower your blood sugar (glucose).
Type 2 diabetes is a disease in which your pancreas does not make enough insulin to control the sugar 
in your blood or where your body does not respond normally to the insulin it produces.
Enyglid is used to control type 2 diabetes in adults as an add-on to diet and exercise: treatment is 
usually started if diet, exercise and weight reduction alone have not been able to control (or lower) 
your blood sugar.
Enyglid can also be given with metformin, another medicine for diabetes.
Enyglid has been shown to lower the blood sugar, which helps to prevent complications from your 
diabetes.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take enyglid"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take enyglid"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Enyglid</p>
<p>if you are allergic to repaglinide or any of the other ingredients of this medicine (listed in 
section 6).</p>
<p>if you have type 1 diabetes.</p>
<p>if the acid level in your blood is raised (diabetic ketoacidosis).</p>
<p>if you have a severe liver disease.</p>
<p>if you take gemfibrozil (a medicine used to lower increased fat levels in the blood).
Warning and precautions
Talk to your doctor before taking Enyglid:</p>
<p>if you have liver problems. Enyglid is not recommended in patients with moderate liver 
disease. Enyglid should not be taken if you have a severe liver disease (see Do not take
Enyglid).</p>
<p>if you have kidney problems. Enyglid should be taken with caution.</p>
<p>if you are about to have major surgery or you have recently suffered a severe illness or 
infection. At such times diabetic control may be lost.</p>
<p>if you are under 18 or over 75 years of age. Enyglid is not recommended. It has not been 
studied in these age groups.
Talk to your doctor if any of the above applies to you. Enyglid may not be suitable for you. Your 
doctor will advise you.
Children and adolescents
Do not take this medicine if you are under 18 years of age.
If you get a hypo (low blood sugar)
You may get a hypo (short for hypoglycaemia) if your blood sugar gets too low. This may happen:</p>
<p>if you take too much Enyglid</p>
<p>if you exercise more than usual</p>
<p>if you take other medicines or suffer from liver or kidney problems (see other sections of </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take enyglid"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take enyglid"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>The warning signs of a hypo may come on suddenly and can include: cold sweat, cool pale skin, 
headache, rapid heart beat, feeling sick, feeling very hungry, temporary changes in vision, drowsiness, 
unusual tiredness and weakness, nervousness or tremor, feeling anxious, feeling confused, difficulty in 
concentrating.
If your blood sugar is low or you feel a hypo coming on eat glucose tablets or a high sugar snack or 
drink, then rest.
When symptoms of hypoglycaemia have disappeared or when blood sugar levels are stabilised
continue repaglinide treatment.
Tell people you have diabetes and that if you pass out (become unconscious) due to a hypo, they 
must turn you on your side and get medical help straight away. They must not give you any food or 
drink. It could choke you.
If severe hypoglycaemia is not treated, it can cause brain damage (temporary or permanent) and even 
death.
If you have a hypo that makes you pass out, or a lot of hypos, talk to your doctor. The amount of 
Enyglid, food or exercise may need to be adjusted.
If your blood sugar gets too high
Your blood sugar may get too high (hyperglycaemia). This may happen:</p>
<p>if you take too little Enyglid,</p>
<p>if you have an infection or a fever,</p>
<p>if you eat more than usual,</p>
<p>if you exercise less than usual.
The warning signs of too high blood sugar appear gradually. They include: increased urination, 
feeling thirsty, dry skin and dry mouth. Talk to your doctor. The amount of Enyglid, food or exercise 
may need to be adjusted.
Other medicines and Enyglid
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.
You can take Enyglid with metformin, another medicine for diabetes, if your doctor prescribes it.
If you take gemfibrozil (used to lower increased fat levels in the blood) you should not take Enyglid.
Your body s response to Enyglid may change if you take other medicines, especially these:</p>
<p>Monoamine oxidase inhibitors (MAOI) (used to treat depression).</p>
<p>Beta blockers (used to treat high blood pressure orheart conditions).</p>
<p>ACE-inhibitors (used to treat heart conditions).</p>
<p>Salicylates (e.g. aspirin).</p>
<p>Octreotide (used to treat cancer).</p>
<p>Nonsteroidal anti-inflammatory drugs (NSAID) (a type of painkillers).</p>
<p>Steroids (anabolic steroids and corticosteroids   used for anemia or to treat inflammation).</p>
<p>Oral contraceptives (birth control pills).</p>
<p>Thiazides (diuretics or  water pills ).</p>
<p>Danazol (used to treat breast cysts and endometriosis).</p>
<p>Thyroid products (used to treat low levels of thyroid hormones).</p>
<p>Sympathomimetics (used to treat asthma).</p>
<p>Clarithromycin, trimethoprim, rifampicin (antibiotic medicines).</p>
<p>Itraconazole, ketokonazole (antifungal medicines).</p>
<p>Gemfibrozil (used to treat high blood fats).</p>
<p>Ciclosporin (used to suppress the immune system).</p>
<p>Deferasirox (used to reduce chronic iron overload)</p>
<p>Clopidogrel (prevents blood clots)</p>
<p>Phenytoin, carbamazepine, phenobarbital (used to treat epilepsy).</p>
<p>St.John s wort (herbal medicine).
Enyglid with alcohol
Alcohol can change the ability of Enyglid to reduce the blood sugar. Watch for signs of a hypo.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before taking this medicine.
You should not take Enyglid if you are pregnant or you are planning to become pregnant.
You should not take Enyglid if you are breast-feeding.
Driving and using machines
Your ability to drive or use a machine may be affected if your blood sugar is low or high. Bear in mind 
that you could endanger yourself or others. Please ask your doctor whether you can drive a car if you:</p>
<p>have frequent hypos,</p>
<p>have few or no warning signs of hypos.
Enyglid contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium-
free .</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not 
sure.
Your doctor will work out your dose.</p>
<p>The normal starting dose is 0.5 mg before each main meal. Swallow the tablets with a glass of 
water immediately before or up to 30 minutes before each main meal.</p>
<p>The dose may be adjusted by your doctor by up to 4 mg to be taken immediately before or up to 
30 minutes before each main meal. The maximum recommended daily dose is 16 mg.
Do not take more Enyglid than your doctor has recommended.
If you take more Enyglid than you should
If you take too many tablets, your blood sugar may become too low, leading to a hypo. Please see If 
you get a hypo on what a hypo is and how to treat it.
If you forget to take Enyglid
If you miss a dose, take the next dose as usual.
Do not take a double dose to make up for a forgotten tablet.
If you stop taking Enyglid
Be aware that the desired effect is not achieved if you stop taking Enyglid. Your diabetes may get 
worse. If any change of your treatment is necessary contact your doctor first.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store enyglid"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store enyglid"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
Hypoglycaemia
The most frequent side effect is hypoglycaemia which may affect up to 1 in 10 people (see If you get a 
hypo in section 2). Hypoglycaemic reactions are generally mild/moderate but may occasionally 
develop into hypoglycaemic unconsciousness or coma. If this happens, medical assistance is needed 
immediately.
Allergy
Allergy is very rare (may affect up to 1 in 10,000 people). Symptoms such as swelling, difficulty in 
breathing, rapid heartbeat, feeling dizzy and sweating could be signs of anaphylactic reaction. Contact 
a doctor immediately.
Other side effects
Common (may affect up to 1 in 10 people):</p>
<p>Stomach pain</p>
<p>Diarrhoea
Rare (may affect up to 1 in 1,000 people):</p>
<p>Acute coronary syndrome (but it may not be due to the medicine).
Very rare (may affect up to 1 in 10,000 people):</p>
<p>Vomiting</p>
<p>Constipation</p>
<p>Visual disturbances</p>
<p>Severe liver problems, abnormal liver function such as, increased liver enzymes in your blood.
Not known (frequency cannot be estimated from the available data):</p>
<p>Hypersensitivity (such as rash, itchy skin, redening of the skin, swelling of the skin)</p>
<p>Feeling sick (nausea)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and outer carton. The 
expiry date refers to the last day of that month.
Store in the original package in order to protect from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment.</p>         </div>"""      



Instance: composition-da-8a64404ab8208188b8002b2af6aa836e
InstanceOf: CompositionUvEpi
Title: "Composition for enyglid Package Leaflet"
Description:  "Composition for enyglid Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp53be401b554c8b8758dbe7f849ef490a)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - enyglid"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen:
1. Virkning og anvendelse
2. Det skal du vide, før du begynder at tage Enyglid
3. Sådan skal du tage Enyglid
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What enyglid is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What enyglid is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Enyglid er en tablet, som indeholder repaglinid, til behandling af sukkersyge til oral anvendelse, som 
får bugspytkirtlen til at producere mere insulin og derved sænker dit blodsukker (glukose).
Type 2-diabetes er en sygdom, hvor bugspytkirtlen ikke producerer tilstrækkelig insulin til at regulere 
dit blodsukker, eller hvor din krop ikke reagerer normalt på insulinet, den producerer.
Enyglid bruges til behandling af type 2-diabetes hos voksne som et supplement til kost og motion: 
Behandling påbegyndes normalt, hvis diæt, motion og vægttab alene ikke har været tilstrækkeligt til at 
regulere (eller reducere) blodsukkeret. 
Enyglid kan også ordineres sammen med metformin, et andet lægemiddel mod sukkersyge.
Enyglid er i stand til at sænke blodsukkeret, hvilket kan hjælpe med til at forhindre komplikationer 
forårsaget af sukkersyge.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take enyglid"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take enyglid"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Enyglid

Hvis du er allergisk over for repaglinid eller et af de øvrige indholdsstoffer i dette lægemiddel
(angivet i punkt 6).

Hvis du har type 1-diabetes.

Hvis syreniveauet i dit blod er forhøjet (diabetisk ketoacidose).

Hvis du har en alvorlig leversygdom.

Hvis du tager gemfibrozil (et lægemiddel der anvendes til at sænke kolesterolniveauet i blodet).
28
Advarsler og forsigtighedsregler
Kontakt lægen før du tager Enyglid:

Hvis du har problemer med din lever. Enyglid anbefales ikke til patienter med moderat 
leversygdom. Du må ikke tage Enyglid, hvis du har en alvorlig leversygdom (se Tag ikke 
Enyglid).

Hvis du har problemer med dine nyrer. Enyglid skal tages med forsigtighed.

Hvis du står over for en stor operation eller lige har overstået en alvorlig sygdom eller
infektion. I sådanne tilfælde kan diabetesreguleringen muligvis gå tabt.

Hvis du er under 18 år eller over 75 år gammel, anbefales det ikke at tage Enyglid, da der ikke 
er lavet studier med disse aldersgrupper.
Fortæl det til din læge, hvis noget af ovennævnte gælder for dig. Enyglid er måske ikke den rigtige 
løsning for dig. Lægen vil rådgive dig.
Børn og teenagere
Tag ikke dette lægemiddel hvis du er under 18 år.
Hvis du får hypoglykæmi (lavt blodsukker)
Du kan få hypoglykæmi, hvis dit blodsukker bliver for lavt. Dette kan ske:

Hvis du tager for mange Enyglid

Hvis du motionerer mere end normalt

Hvis du tager anden medicin eller lider af lever- eller nyreproblemer (se andre afsnit under 
punkt </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take enyglid"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take enyglid"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Advarselstegn på hypoglykæmi kan opstå pludseligt og kan medføre: koldsved, kold bleg hud, 
hovedpine, hjertebanken, kvalme, stærk fornemmelse af sult, midlertidige synsændringer, døsighed, 
usædvanlig træthed og svaghed, nervøsitet eller rysten, følelse af uro, forvirring, 
koncentrationsbesvær.
Hvis dit blodsukker er lavt, eller hvis du mærker symptomer på begyndende hypoglykæmi: spis 
glucosetabletter, tag en snack eller drik noget med et højt sukkerindhold. Hvil derefter.
Når symptomerne på hypoglykæmi er forsvundet, og blodsukkerniveauet er stabiliseret, kan du 
fortsætte behandlingen med Enyglid.
Fortæl din omgangskreds at du har sukkersyge, og at du - hvis du mister bevidstheden
(besvimer) på grund af hypoglykæmi - skal vendes om på siden, og der straks skal tilkaldes lægehjælp. 
Du må ikke få mad eller drikke, da du kan blive kvalt.
Hvis alvorlig hypoglykæmi ikke behandles, kan det forårsage hjerneskade (midlertidig eller 
permanent) og endog død.
Hvis du har hypoglykæmi, som får dig til at besvime, eller hvis du har mange tilfælde af 
hypoglykæmi, skal du tale med din læge. Mængden af Enyglid, mad eller motion skal muligvis 
justeres.
Hvis dit blodsukker bliver for højt
Dit blodsukker kan blive for højt (hyperglykæmi). Dette kan ske:

Hvis du har taget for få Enyglid,

Hvis du har en infektion eller feber,

Hvis du spiser mere end normalt,

Hvis du motionerer mindre end normalt.
Advarselstegnene på for højt blodsukker optræder gradvist. De inkluderer: øget vandladningstrang, 
tørstfornemmelse, tør hud og tør mund. Tal med din læge, da mængden af Enyglid, mad eller motion 
muligvis skal justeres.
Brug af anden medicin sammen med Enyglid
Fortæl det altid til lægen eller apotekspersonalet, hvis du bruger anden medicin, for nylig har brugt 
anden medicin eller planlægger at bruge anden medicin.
Du kan tage Enyglid sammen med metformin, et andet lægemiddel mod sukkersyge, hvis din læge 
29
ordinerer det.
Hvis du tager gemfibrozil (anvendes til at sænke kolesterolniveauet i blodet), må du ikke tage Enyglid.
Din krops reaktion på Enyglid kan ændres, hvis du tager anden medicin, især følgende:

Monoaminooxidasehæmmere eller MAO-hæmmere (mod depression).

Betablokkere (mod forhøjet blodtryk eller hjertelidelser).

ACE-hæmmere (mod hjertelidelser).

Salicylater (f.eks. aspirin).

Oktreotid (mod kræft).

Nonsteroide antiinflammatoriske midler (NSAID) (en gruppe af smertestillende midler).

Steroider (anaboliske steroider og kortikosteroider - mod blodmangel eller mod inflammation).

Orale kontraceptiva (p-piller).

Thiazider (vanddrivende tabletter).

Danazol (mod brystcyster og endometriose).

Thyreoideapræparater (mod lavt niveau af skjoldbruskkirtlens hormoner).

Sympatomimetika (mod astma).

Clarithromycin, trimethoprim, rifampicin (antibiotiske lægemidler).

Itraconazol, ketokonazol (svampehæmmende lægemidler).

Gemfibrozil (mod kolesterol i blodet).

Ciclosporin (anvendes til at undertrykke immunsystemet).

Deferasirox (anvendes til at mindske kronisk jernoverskud).

Clopidogrel (forebygger blodpropper).

Phenytoin, carbamazepin, phenobarbital (mod epilepsi).

Perikum (naturlægemiddel).
Brug af Enyglid sammen med alkohol
Alkohol kan ændre den virkning, som Enyglid har til at sænke blodsukkeret. Vær opmærksom på 
hypoglykæmiske tegn.
Graviditet og amning
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel.
Du må ikke tage Enyglid, hvis du er gravid eller planlægger at blive det.
Du må ikke tage Enyglid, hvis du ammer.
Trafik- og arbejdssikkerhed
Din evne til at køre bil, motorcykel eller cykle samt arbejde med maskiner, kan muligvis være 
påvirket, hvis dit blodsukker er for lavt eller for højt. Husk, at du kan bringe dig selv og andre i fare. 
Spørg venligst din læge om du kan køre bil, hvis du:

Ofte har hypoglykæmi

Har få eller ingen advarselstegn på hypoglykæmi.
Enyglid indeholder natrium
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl så spørg lægen.
Lægen vil bestemme din dosis.
30

Den sædvanlige startdosis er 0,5 mg før hvert hovedmåltid. Tabletterne sluges sammen med et 
glas vand før eller op til 30 minutter før hvert hovedmåltid.

Dosis kan justeres af lægen med op til 4 mg, som skal tages umiddelbart før eller op til minutter før hvert hovedmåltid. Den højeste anbefalede daglige dosis er 16 mg.
Tag aldrig en større mængde Enyglid, end lægen har anbefalet.
Hvis du har taget for meget Enyglid
Hvis du tager for mange tabletter, kan det sænke blodsukkerniveauet for meget og medføre
hypoglykæmi. Se Hvis du får hypoglykæmi (lavt blodsukker) med hensyn til hvad hypoglykæmi er og 
hvordan det behandles.
Hvis du har glemt at tage Enyglid
Hvis du glemmer at tage en dosis, skal du tage den næste dosis som sædvanligt. Du må ikke tage en
dobbeltdosis som erstatning for den glemte dosis.
Hvis du stopper med at tage Enyglid
Vær opmærksom på at den ønskede virkning ikke opnås, hvis du stopper med at tage Enyglid. Din
diabetes kan forværres. Hvis det er nødvendigt at ændre din behandling er nødvendig, skal du først 
kontakte din læge.
Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store enyglid"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store enyglid"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.
Hypoglykæmi
Hypoglykæmi er den mest almindelige bivirkning og kan forekomme hos mellem 1 og 10 ud af personer (se Hvis du får hypoglykæmi (lavt blodsukker), under punkt 2). Hypoglykæmiske reaktioner 
er sædvanligvis milde til moderate, men kan i nogle tilfælde udvikle sig til hypoglykæmisk 
bevidstløshed eller koma. Hvis dette sker, har du brug for øjeblikkelig lægehjælp.
Allergi
Allergi er meget sjældent (kan forekomme hos færre end 1 ud af 10.000 personer). Symptomer såsom 
hævelse, vejrtrækningsbesvær, hjertebanken, svimmelhed, svedeture, kan være tegn på en anafylaktisk 
reaktion. Kontakt straks en læge.
Andre bivirkninger
Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer):

Mavesmerter

Diarré.
Sjældne bivirkninger (kan forekomme hos op til 1 ud af 1.000 personer):

Akut koronarsyndrom (men det behøver ikke være forårsaget af lægemidlet).
Meget sjældne bivirkninger (kan forekomme hos op til 1 ud af 10.000 personer):

Opkastning

Forstoppelse

Synsforstyrrelser

Alvorlige leverproblemer, unormal leverfunktion, såsom stigning af leverenzymer i blodet.
Ikke kendt (kan ikke estimeres ud fra tilgængeligt data):

Hypersensitivitet (såsom udslæt, kløe, rødmen, hævelse af huden)

Kvalme.
31
Indberetning af bivirkninger
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar dette lægemiddel utilgængeligt for børn.
Brug ikke lægemidlet efter den udløbsdato, der står på blisterpakningen og den ydre æske. 
Udløbsdatoen er den sidste dag i den nævnte måned.
Opbevares i den originale yderpakning for at beskytte mod lys.
Spørg apotekspersonalet hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden.</p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-8a64404ab8208188b8002b2af6aa836e
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for enyglid Package Leaflet for language en"
Description: "ePI document Bundle for enyglid Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-8a64404ab8208188b8002b2af6aa836e"
* entry[0].resource = composition-en-8a64404ab8208188b8002b2af6aa836e

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8a64404ab8208188b8002b2af6aa836e"
* entry[=].resource = mp8a64404ab8208188b8002b2af6aa836e
                            
                    
Instance: bundlepackageleaflet-da-8a64404ab8208188b8002b2af6aa836e
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for enyglid Package Leaflet for language da"
Description: "ePI document Bundle for enyglid Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-8a64404ab8208188b8002b2af6aa836e"
* entry[0].resource = composition-da-8a64404ab8208188b8002b2af6aa836e

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8a64404ab8208188b8002b2af6aa836e"
* entry[=].resource = mp8a64404ab8208188b8002b2af6aa836e
                            
                    



Instance: mp8a64404ab8208188b8002b2af6aa836e
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product enyglid"
Description: "enyglid"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "Enyglid 0.5 mg tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "enyglid"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 8a64404ab8208188b8002b2af6aa836eListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "enyglid"

* status = #current
* mode = #working

* title = "List of all ePIs associated with enyglid"

* subject = Reference(mp53be401b554c8b8758dbe7f849ef490a)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#enyglid "enyglid"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-8a64404ab8208188b8002b2af6aa836e) // enyglid en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-8a64404ab8208188b8002b2af6aa836e) // enyglid da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-8a64404ab8208188b8002b2af6aa836e
InstanceOf: List

* insert 8a64404ab8208188b8002b2af6aa836eListRuleset
    